GlassScriptPhysician profile
Jean-Pierre Obeid
NPI 1770012411
$29,768.39
in general payments reported to CMS, 2019-2025
8 companies · $188 in 2025
The $188 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $155 · 2022: $15K · 2023: $2,230 · 2024: $12K · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Education: $500 · Travel and Lodging: $443 · Food and Beverage: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,482.00 |
| Education | $500.00 |
| Travel and Lodging | $443.26 |
| Food and Beverage | $330.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mim Software INC. | $28,257.00 | 2022-2024 | Contour Protege Ai |
| Carl Zeiss Meditec USA, INC. | $1,026.33 | 2022-2023 | Intrabeam |
| Boston Scientific Corporation | $149.00 | 2023-2025 | Spaceoar Vue System - 10ml |
| Heron Therapeutics, INC. | $124.96 | 2021 | |
| Depuy Synthes Sales INC. | $65.63 | 2025 | Na |
| Caris Mpi, INC. | $65.06 | 2025 | Mi Cancer Seek |
| Novocure INC. | $50.48 | 2024-2025 | Optune Lua (Novottf-200t) |
| Abbvie INC. | $29.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean-Pierre Obeid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.